Link to this page
National Cancer Institute Thesaurus
Last uploaded:
June 2, 2026
| Id | http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C97941
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C97941
|
|---|---|
| Preferred Name | Ponezumab |
| Definitions |
A humanized monoclonal antibody (IgG2deltaA) raised against amyloid beta peptides with Alzheimer disease treatment application. Ponezumab recognizes and binds the free carboxy terminal amino acids 33-40 of the amyloid beta peptide 1-40 and may be used in a passive immunotherapy treatment.
|
| Synonyms |
PF-04360365
Anti-human beta-amyloid Monoclonal Antibody PF-04360365
PONEZUMAB
Ponezumab
RN-1219
|
| Type | http://www.w3.org/2002/07/owl#Class |
All Properties
| label | Ponezumab
|
|---|---|
| prefixIRI | Thesaurus:C97941
|
| code | C97941
|
| DEFINITION | A humanized monoclonal antibody (IgG2deltaA) raised against amyloid beta peptides with Alzheimer disease treatment application. Ponezumab recognizes and binds the free carboxy terminal amino acids 33-40 of the amyloid beta peptide 1-40 and may be used in a passive immunotherapy treatment.
|
| Contributing_Source | FDA
|
| Accepted_Therapeutic_Use_For | Treatment of Alzheimer's disease
|
| FULL_SYN |
PF-04360365
Anti-human beta-amyloid Monoclonal Antibody PF-04360365
PONEZUMAB
Ponezumab
RN-1219
|
| Chemical_Formula | C6552H10158N1730O2090S52
|
| UMLS_CUI | C3273712
|
| FDA_UNII_Code | 1TG15H1XE9
|
| Preferred_Name | Ponezumab
|
| type | |
| subClassOf | |
| CAS_Registry | 1178862-65-1
|
| Concept_In_Subset | |
| Semantic_Type |
Amino Acid, Peptide, or Protein
Pharmacologic Substance
Immunologic Factor
|
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |